Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Investments: 2017-2024

Historic Long-Term Investments for Protagonist Therapeutics (PTGX) over the last 3 years, with Dec 2024 value amounting to $140.3 million.

  • Protagonist Therapeutics' Long-Term Investments fell 10.38% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year decrease of 10.38%. This contributed to the annual value of $140.3 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Long-Term Investments is $140.3 million, which was up 6,915.00% from $2.0 million recorded in FY2020.
  • Protagonist Therapeutics' 5-year Long-Term Investments high stood at $140.3 million for FY2024, and its period low was $2.0 million during FY2020.
  • Its 1-year average for Long-Term Investments is $140.3 million, with a median of $140.3 million in 2024.